Notice: This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends LCAP vs. COEP, PULM, PSTV, OTRK, APM, GLTO, HCTI, CANF, EGRX, and MBRXShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Coeptis Therapeutics (COEP), Pulmatrix (PULM), Plus Therapeutics (PSTV), Ontrak (OTRK), Aptorum Group (APM), Galecto (GLTO), Healthcare Triangle (HCTI), Can-Fite BioPharma (CANF), Eagle Pharmaceuticals (EGRX), and Moleculin Biotech (MBRX). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Coeptis Therapeutics Pulmatrix Plus Therapeutics Ontrak Aptorum Group Galecto Healthcare Triangle Can-Fite BioPharma Eagle Pharmaceuticals Moleculin Biotech Coeptis Therapeutics (NASDAQ:COEP) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Does the MarketBeat Community favor COEP or LCAP? Coeptis Therapeutics received 5 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users. CompanyUnderperformOutperformCoeptis TherapeuticsOutperform Votes583.33% Underperform Votes116.67%Lionheart Acquisition Co. IIN/AN/A Does the media favor COEP or LCAP? In the previous week, Lionheart Acquisition Co. II's average media sentiment score of 0.00 beat Coeptis Therapeutics' score of -1.00 indicating that Lionheart Acquisition Co. II is being referred to more favorably in the news media. Company Overall Sentiment Coeptis Therapeutics Negative Lionheart Acquisition Co. II Neutral Do analysts rate COEP or LCAP? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is COEP or LCAP more profitable? Lionheart Acquisition Co. II's return on equity of -44.30% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -5,710.19% -413.75% Lionheart Acquisition Co. II N/A -44.30%1.39% Which has higher earnings and valuation, COEP or LCAP? Lionheart Acquisition Co. II has lower revenue, but higher earnings than Coeptis Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis Therapeutics$80K98.31-$21.27M-$0.47-0.42Lionheart Acquisition Co. IIN/AN/A$3.21MN/AN/A Do insiders & institutionals have more ownership in COEP or LCAP? 13.9% of Coeptis Therapeutics shares are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 19.4% of Lionheart Acquisition Co. II shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, COEP or LCAP? Coeptis Therapeutics has a beta of -0.91, meaning that its stock price is 191% less volatile than the S&P 500. Comparatively, Lionheart Acquisition Co. II has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. SummaryLionheart Acquisition Co. II beats Coeptis Therapeutics on 5 of the 9 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98M$314.29M$5.50B$8.53BDividend YieldN/A5.03%5.13%4.14%P/E RatioN/A803.50116.1015.23Price / SalesN/A102.551,496.2597.74Price / Cash20.6415.8039.7434.10Price / Book-0.042.524.775.07Net Income$3.21M$1.34M$119.06M$225.46M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$0.11+10.3%N/A-96.1%$1.98MN/A0.003Gap UpHigh Trading VolumeCOEPCoeptis Therapeutics0.4813 of 5 stars$0.20flatN/A-83.6%$7.87M$80,000.00-0.422Short Interest ↑Negative NewsGap DownPULMPulmatrix0.3253 of 5 stars$2.13-3.2%N/A+12.7%$7.78M$11.39M-0.7220Analyst ForecastPSTVPlus Therapeutics3.2614 of 5 stars$1.35+3.1%$14.00+937.0%+4.7%$7.75M$4.91M-0.4320Upcoming EarningsOTRKOntrak2.1981 of 5 stars$1.85+2.2%$45.00+2,332.4%-88.7%$7.63M$12.39M-0.05250Negative NewsGap UpAPMAptorum Group0.9134 of 5 stars$1.45+1.4%N/A-13.0%$7.53M$430,000.000.0030GLTOGalecto3.1621 of 5 stars$6.83-0.3%$10.00+46.4%-47.5%$7.45MN/A-0.2940Upcoming EarningsNews CoverageHCTIHealthcare Triangle0.7238 of 5 stars$1.29-5.1%N/A-68.1%$7.31M$33.20M-0.5322Gap UpCANFCan-Fite BioPharma1.4306 of 5 stars$2.04-5.1%$18.00+782.4%-4.2%$7.22M$740,000.00-1.148Analyst DowngradeEGRXEagle Pharmaceuticals2.1262 of 5 stars$0.55-8.3%N/A-96.1%$7.14M$257.55M0.00134News CoverageGap UpMBRXMoleculin Biotech1.9509 of 5 stars$2.45-5.8%$35.00+1,328.6%-66.1%$6.97MN/A0.0020 Related Companies and Tools Related Companies COEP Alternatives PULM Alternatives PSTV Alternatives OTRK Alternatives APM Alternatives GLTO Alternatives HCTI Alternatives CANF Alternatives EGRX Alternatives MBRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LCAP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
